MedTrace Logo

Effects of β-glucans on Gut Permeability and Microbiota in Elderly

NCT05584254 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-03-23

No results posted yet for this study

Summary

The investigators aim was to compare healthy young adults, senior orienteers (model of healthy ageing) and elderly with gastrointestinal symptoms on intestinal permeability, microbiota compositions and well-being. In addition, assess whether 3 weeks of oral intake of soluble or dispersible forms yeast-dervied beta-glucan could improve intestinal barrier function against drug-induced barrier disruption vs placebo for a cohort of elderly people with gastrointestinal symptoms, in a randomized double blinded placebo-controlled cross-over clinical trial.

Conditions

  • Elderly
  • Bowel Symptoms
  • Prebiotics

Interventions

DIETARY_SUPPLEMENT

yeast-beta glucan

Sponsors & Collaborators

  • Kerry Group

    collaborator UNKNOWN

  • Örebro University, Sweden

    lead OTHER

Principal Investigators

  • Robert J Brummer, PhD/MD · Örebro University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2017-08-14
Completion
2017-08-14

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584254 on ClinicalTrials.gov